Melanoma News & Features
Cause-specific mortality similar for women and girls with pregnancy-associated MM or non-PAMM.
A key discovery has advanced the understanding of why some patients respond to ipilimumab, an immunotherapy drug, whereas others show less response.
Nivolumab and dabrafenib plus trametinib up survival in melanoma without, with BRAF, respectively.
There may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.
Treatment with a combination of the drugs sargramostim plus ipilimumab, rather than ipilimumab alone, yielded longer overall survival and lower toxicity for patients with metastatic melanoma.
- Key discovery in understanding successes and failures of immunotherapy
- Researchers identify biological indicator of response to new ovarian cancer drug
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Reducing side effects of everolimus administration
- Navigation and survivorship: Rationalizing your program costs
- Monitoring psychosocial function in radiotherapy
- Comparison of medications for managing nausea and vomiting
- Comparison of constipation management medications
- Chemo- and immunotherapy combination is a promising treatment for pancreatic cancer
- High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone
- Hair Dyes and Cancer Risk (Fact Sheet)
- For bladder cancer, laparoscopic radical cystectomy effective at preventing recurrence
- Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
- Modifying lifestyle, HPV vaccine can help prevent anal cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|